The effect of Eye Movement Desensitization and Reprocessing (EMDR) on Illness Anxiety Disorder (IAD): two multiple baseline n-of-1 trials across seven participants each.

The effect of Eye Movement Desensitization and Reprocessing (EMDR) on Illness Anxiety Disorder (IAD): two multiple baseline n-of-1 trials across seven participants each. - EMDR4IAD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON51800

Enrollment

Registered

2023-02-10

Start date

2023-02-14

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypochondria illness anxiety disorder

Interventions

EMDR (Eye Movement and Desensitization Disorder)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: >18 years DSM-5 diagnosis of an Illness Anxiety Disorder

Exclusion criteria

Exclusion criteria: Participants will be excluded from participating in this study if they are currently under treatment for their IAD or receive any psychological or pharmaceutical treatment for another disorder or problem. Exceptions will be made for patients who are currently treated with selective serotonin reuptake inhibitors (SSRI*s) and on a stable dose for the last 3 months. Additionally, participants will be excluded if they can*t read and comprehend Dutch language, and if they are unable to give informed consent because of mental incapacity.

Design outcomes

Primary

Measure	Time frame
The daily Idiopathic illness anxiety scale (IIAS).	—

Secondary

Measure	Time frame
SCID-5-S, SCL-90 en BDI-II-NL, WI, IAS and PCL-5	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)